A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Saudi Pharmaceutical Journal Pub Date : 2024-10-24 DOI:10.1016/j.jsps.2024.102192
{"title":"A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities","authors":"","doi":"10.1016/j.jsps.2024.102192","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Saudi Arabia has experienced an increasing trend in obesity prevalence in the last three decades; obesity is a significant risk factor for non-communicable diseases, which may cause healthcare and economic burdens. In this systematic review, we aim to explore the obesity prevalence, obesity-related complications (ORCs), and the economic burden of obesity in Saudi Arabia.</div></div><div><h3>Methods</h3><div>Literature searches for relevant local studies across Saudi Arabia spanning 2012 to 2022 were performed in PubMed and EMBASE, along with supplementary searches for relevant congress abstracts. Only studies that discussed obesity prevalence in Saudi Arabia in relation to any gender or age group, the prevalence of ORCs in Saudi Arabia for any gender or age group, and/or the economic burden of obesity and how it impacts the healthcare system in Saudi Arabia, and were published in the English language, were selected for inclusion. No age or gender restrictions were imposed.</div></div><div><h3>Results</h3><div>The prevalence of obesity in Saudi Arabia ranged from 20% to 39% and up to 19.4% among adults and adolescents, respectively. The most reported ORCs were hypertension (67.6%), type 2 diabetes (60.7%), and hypercholesterolaemia (51.3%), and an association between obesity and ORCs was established, showing an increased risk with increasing body mass index. The economic burden of obesity across Saudi Arabia was estimated to be 6.4 billion US dollars (USD) for treatment and management.</div></div><div><h3>Conclusion</h3><div>Obesity affects a substantial proportion of the Saudi general population and is a significant burden on individuals, as demonstrated by the prevalence of ORCs. Multifaceted, short- and long-term approaches involving interventions that operate at multiple levels and target both individuals and communities are urgently needed; there is a particular need for a national strategy and a specific, systems-based policy. Further research will help increase awareness of obesity and its management, which will be crucial for transforming the healthcare system under <span><span>Vision 2030</span></span>.</div></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Pharmaceutical Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1319016424002433","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Saudi Arabia has experienced an increasing trend in obesity prevalence in the last three decades; obesity is a significant risk factor for non-communicable diseases, which may cause healthcare and economic burdens. In this systematic review, we aim to explore the obesity prevalence, obesity-related complications (ORCs), and the economic burden of obesity in Saudi Arabia.

Methods

Literature searches for relevant local studies across Saudi Arabia spanning 2012 to 2022 were performed in PubMed and EMBASE, along with supplementary searches for relevant congress abstracts. Only studies that discussed obesity prevalence in Saudi Arabia in relation to any gender or age group, the prevalence of ORCs in Saudi Arabia for any gender or age group, and/or the economic burden of obesity and how it impacts the healthcare system in Saudi Arabia, and were published in the English language, were selected for inclusion. No age or gender restrictions were imposed.

Results

The prevalence of obesity in Saudi Arabia ranged from 20% to 39% and up to 19.4% among adults and adolescents, respectively. The most reported ORCs were hypertension (67.6%), type 2 diabetes (60.7%), and hypercholesterolaemia (51.3%), and an association between obesity and ORCs was established, showing an increased risk with increasing body mass index. The economic burden of obesity across Saudi Arabia was estimated to be 6.4 billion US dollars (USD) for treatment and management.

Conclusion

Obesity affects a substantial proportion of the Saudi general population and is a significant burden on individuals, as demonstrated by the prevalence of ORCs. Multifaceted, short- and long-term approaches involving interventions that operate at multiple levels and target both individuals and communities are urgently needed; there is a particular need for a national strategy and a specific, systems-based policy. Further research will help increase awareness of obesity and its management, which will be crucial for transforming the healthcare system under Vision 2030.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
沙特阿拉伯肥胖负担的系统回顾:患病率及相关并发症
导言沙特阿拉伯在过去三十年中肥胖症发病率呈上升趋势;肥胖症是非传染性疾病的重要风险因素,可能会造成医疗保健和经济负担。在这篇系统性综述中,我们旨在探讨沙特阿拉伯的肥胖患病率、肥胖相关并发症(ORCs)以及肥胖造成的经济负担。方法我们在 PubMed 和 EMBASE 中检索了 2012 年至 2022 年期间沙特阿拉伯当地的相关研究,并补充检索了相关的大会摘要。只有讨论沙特阿拉伯任何性别或年龄组的肥胖患病率、沙特阿拉伯任何性别或年龄组的ORC患病率、和/或肥胖的经济负担及其如何影响沙特阿拉伯的医疗保健系统,并以英语发表的研究才被选入。结果沙特阿拉伯成年人和青少年的肥胖患病率分别为 20% 至 39%,最高达 19.4%。报告最多的器官功能障碍是高血压(67.6%)、2 型糖尿病(60.7%)和高胆固醇血症(51.3%),肥胖与器官功能障碍之间存在关联,表明随着体重指数的增加,风险也会增加。据估计,沙特阿拉伯全国因肥胖症造成的治疗和管理经济负担达 64 亿美元。亟需采取多方面、短期和长期的方法,在多个层面开展针对个人和社区的干预活动;尤其需要制定国家战略和以系统为基础的具体政策。进一步的研究将有助于提高人们对肥胖症及其管理的认识,这对于根据《2030 年远景规划》转变医疗保健系统至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Saudi Pharmaceutical Journal
Saudi Pharmaceutical Journal PHARMACOLOGY & PHARMACY-
CiteScore
6.10
自引率
2.40%
发文量
194
审稿时长
67 days
期刊介绍: The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical Society, with the cooperation of the College of Pharmacy, King Saud University.
期刊最新文献
Inside Front Cover - Editorial Board Otostegia fruticosa (Forssk.) – A comprehensive insight of its ethnopharmacology, phytochemistry, and pharmacological activities Cytochrome c and cancer cell metabolism: A new perspective Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1